Rhythm Pharmaceuticals Inc [RYTM] stock is trading at $89.0, up 36.63%. An important factor to consider is whether the stock is rising or falling in short-term value. The RYTM shares have gain 36.00% over the last week, with a monthly amount glided 30.67%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Rhythm Pharmaceuticals Inc [NASDAQ: RYTM] stock has seen the most recent analyst activity on July 07, 2025, when Leerink Partners initiated its Outperform rating and assigned the stock a price target of $88. Previously, BofA Securities upgraded its rating to Buy on April 07, 2025, and kept the price target unchanged to $63. Jefferies started tracking the stock assigning a Buy rating and suggested a price target of $80 on January 02, 2025. Oppenheimer initiated its recommendation with a Outperform and recommended $76 as its price target on December 20, 2024. Guggenheim started tracking with a Buy rating for this stock on October 21, 2024, and assigned it a price target of $70. In a note dated September 18, 2024, H.C. Wainwright initiated an Buy rating and provided a target price of $64 on this stock.
Rhythm Pharmaceuticals Inc [RYTM] stock has fluctuated between $40.61 and $69.89 over the past year. Currently, Wall Street analysts expect the stock to reach $74 within the next 12 months. Rhythm Pharmaceuticals Inc [NASDAQ: RYTM] shares were valued at $89.0 at the most recent close of the market. An investor can expect a potential drop of -16.85% based on the average RYTM price forecast.
Analyzing the RYTM fundamentals
Rhythm Pharmaceuticals Inc [NASDAQ:RYTM] reported sales of 136.86M for the trailing twelve months, which represents a growth of 25.94%. Gross Profit Margin for this corporation currently stands at 0.89% with Operating Profit Margin at -1.26%, Pretax Profit Margin comes in at -1.23%, and Net Profit Margin reading is -1.24%. To continue investigating profitability, this company’s Return on Assets is posted at -0.44, Equity is -1.8 and Total Capital is -0.63. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of0.02.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 79.66 points at the first support level, and at 70.31 for the second support level. However, for the 1st resistance point, the stock is sitting at 93.70, and for the 2nd resistance point, it is at 98.39.
Ratios To Look Out For
For context, Rhythm Pharmaceuticals Inc’s Current Ratio is 3.30. On the other hand, the Quick Ratio is 3.13, and the Cash Ratio is 0.95. Considering the valuation of this stock, the price to sales ratio is 41.37, the price to book ratio is 298.26.
Transactions by insiders
Recent insider trading involved CHRISTOPHER PAUL GERMAN, Officer, that happened on Jul 09 ’25 when 3817.0 shares were purchased. Officer, PAMELA CRAMER completed a deal on Jul 09 ’25 to buy 15572.0 shares. Meanwhile, Officer HUNTER SMITH bought 42120.0 shares on Jul 09 ’25.
